Eicosanoids in Immune Regulation

  • T. J. Rogers
Part of the Advances in Eicosanoid Research book series (AEIR, volume 3)

Abstract

The analysis of the role of the products of the lipoxygenase (LO) pathway of arachidonic acid metabolisn in the immune system has consumed a great deal of attention recently. It is clear that the biochemical events involved in the metabolism of arachidonic acid are still not fully defined, and it is reasonable to assume that our appreciation of the role of LO products in various biological responses is far from complete. Until the present time, studies have been conducted either with purified LO products or with certain ‘specific’ inhibitors of LO activity. Our ability to identify, and purify, additional LO products and inhibitors will certainly assist in the understanding of the role of this pathway in the immune response. Our understanding of the precise immune cell target of the effect of these LO products is still evolving, as is our information concerning the biochemical events which mediate their effects. Finally, we are still in the process of dissecting the cellular and molecular nature of immune responses; thus, information derived from experiments conducted with LO products and inhibitors must be evaluated with the understanding that the mechanism of any effect may be uncertain until a later time.

Keywords

Arachidonic Acid Accessory Cell Arachidonic Acid Metabolism Arachidonic Acid Metabolite Primary Antibody Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Razin, E. (1985). Activation of the 5-lipoxygenase pathway in E-mast cells by peanut agglutinin. J. Immunol, 134, 1142–1145PubMedGoogle Scholar
  2. 2.
    Rigaud, M., Durand, J. and Breton, J.C. (1979). Transformation of arachidonic acid into 12-hydroxy-5,8,10,14-eicosatetraenoic acid by mouse peritoneal macrophages. Biochim. Biophys. Acta, 573, 408–412PubMedGoogle Scholar
  3. 3.
    Yecies, L.D., Wedner, H.J. and Parker, C.W. (1979). Slow reacting substance (SRS) from ionophore A23187-stimulated human leukemic basophils. I. Evidence for a precursor role of arachidonic acid and initial purification. J. Immunol, 123, 2814–2816PubMedGoogle Scholar
  4. 4.
    Rankin, J.A., Hitchcock, M., Merrill, W.W., Huang, S.S., Brashler, J.R., Bach. M.K. and Askenase, P.W. (1984). IgE immune complexes induce immediate and prolonged release of leukotriene C4 (LTC4) from rat alveolar macrophages. J. Immunol, 132, 1993–1999PubMedGoogle Scholar
  5. 5.
    Rouzer, C.A., Scott, W.A., Cohn, Z.A., Blackburn, P. and Manning, J.M. (1980). Mouse peritoneal macrophages release leukotriene C in response to phagocytic stimulus. Proc. Natl. Acad. Sci. USA, 77, 4928–4932PubMedCrossRefGoogle Scholar
  6. 6.
    Williams, J.D., Czop, J.K. and Austen, K.F. (1984). Release of leukotrienes by human monocytes on stimulation of their phagocytic receptor for particulate activators. J. Immunol, 132, 3034–3040PubMedGoogle Scholar
  7. 7.
    Williams, J.D., Lee, T.H., Lewis, R.A. and Austen, K.F. (1985). Intracellular retention of the 5-lipoxygenase pathway product, leukotriene B„ by human neutrophils activated with unopsonized zymosan. J. Immunol, 134, 2624–2630PubMedGoogle Scholar
  8. 8.
    Scott, W.A., Pawlowski, N.A., Andreach, M. and Cohn, Z.A. (1982). Resting macrophages produce distinct metabolites from exogenous arachidonic acid. J. Exp. Med, 155, 535–547PubMedCrossRefGoogle Scholar
  9. 9.
    Scott, W.A., Pawlowski, N.A., Murray, H.W. Andreach, M., Zrike, J. and Cohn, Z.A. (1982). Regulation of arachidonic acid metabolism by macrophage activation. J. Exp. Med, 155, 1148–1160PubMedCrossRefGoogle Scholar
  10. 10.
    Goetzl, E.J., Hill, H.R. and Gorman, R.R. (1980). Unique aspects of the modulation of human neutrophil function by 12-L-hydroperoxy-5,8,10,14-eicosatetraenoic acid. Prostaglandins, 19, 71–85PubMedCrossRefGoogle Scholar
  11. 11.
    Ford-Hutchinson, A.W., Bray, M.A., Doig, M.V., Shipley, M.E. and Smith, M.J. (1980). Leukotriene B„ a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature (London), 286, 264–265CrossRefGoogle Scholar
  12. 12.
    Dahinden, C.A., Clancy, R.M. and Hugli, T.E. (1984). Stereospecificity of leukotriene B, and structure-function relationships for chemotaxis of human neutrophils. J. Immunol, 133, 1477–1482PubMedGoogle Scholar
  13. 13.
    Dessein, A.J., Lee, T.H., Elsas, P., Ravalese, J., III, Silberstein, D., David, J.R., Austen, K.F. and Lewis, R.A. (1986). Enhancement by monokines of leukotriene generation by human eosinophils and neutrophils stimulated with calcium ionophore A23187. J. Immunol, 136, 3829–3838PubMedGoogle Scholar
  14. 14.
    Chang, J., Gilman, S.C. and Lewis, A.J. (1986). Interleukin I activates phospholipase A, in rabbit chondrocytes: a possible signal for IL I action. J. Immunol, 136, 1283–1287PubMedGoogle Scholar
  15. 15.
    Levine, L. and Xiao, D-M. (1985). The stimulations of arachidonic acid metabolism by recombinant murine interleukin 1 and tumor promoters or 1-oleoyl-2-acetyl-glycerol are synergistic. J. Immunol, 135, 3430–3433PubMedGoogle Scholar
  16. 16.
    Rola-Pleszczynski, M. and Lemaire, I. (1985). Leukotrienes augment interleukin 1 production by human monocytes. J. Immunol, 135, 3958–3961PubMedGoogle Scholar
  17. 17.
    Dinarello, C.A., Bishai, I., Rosenwasser, L.J. and Coceano, F. (1984). The influence of lipoxygenase inhibitors on the in vitro production of human leukocytic pyrogen and lymphocyte activating factor (interleukin-1). Int. J. Immunopharmacol, 6, 43–48PubMedCrossRefGoogle Scholar
  18. 18.
    Webb, D.R., Nowowiejski, I., Healy, C. and Rogers, T.J. (1982). Immunosuppressive properties of leukotriene D4 and E4 in vitro, Biochem. Biophys. Res. Commun, 104, 1617–1622PubMedCrossRefGoogle Scholar
  19. 19.
    Melmon, K.L., Weinstein, Y., Shearer, G.M. and Boume, H.R. (1975). Leukocyte separation on the basis of their receptors for biogenic amines and prostaglandins: relation of the receptor to antibody formation. In Braun, W., Lichtenstein, L. and Parker, C.W. (eds.) Camp, Cell Growth and the Immune Response. pp. 114–134. (New York: Springer-Verlag)Google Scholar
  20. 20.
    Plescia, O.J., Smith, A.H. and Grinwich, K. (1975). Subversion of immune systems by tumor cells and role of prostaglandins. Proc. Natl. Acad. Sci. USA, 72, 1848–1851PubMedCrossRefGoogle Scholar
  21. 21.
    Webb, D.R. and Nowowiejski, I. (1977). The role of prostaglandins in the control of the primary 19S immune response to SRBC. Cell. Immunol, 33, 1–10PubMedCrossRefGoogle Scholar
  22. 22.
    Zimecki, M. and Webb, D.R. (1976). The regulation of the immune response to T-independent antigens by prostaglandins and B cells. J. Immunol, 117, 2158–2164PubMedGoogle Scholar
  23. 23.
    Loose, L.D. and DiLuzio, N.R. (1973). Effect of prostaglandin E, on cellular and humoral immune responses. J. Reticuloendothel. Soc, 13, 70–77PubMedGoogle Scholar
  24. 24.
    Wieder, K.J. and Webb, D.R. (1981). The effect of prostaglandin metabolism on immunoglobulin and antibody production in naive and educated whole spleen cells. Prostaglandl. Med, 7, 79–90CrossRefGoogle Scholar
  25. 25.
    Cook, R.G., Stavisky, A.B. and Harold, W.W. (1978). Regulation of the in vitro anamnestic antibody response by cyclic AMP. II. Antigen-dependent enhancement by exogenous prostaglandins of the E series. Cell, Immunol, 40, 128–140PubMedCrossRefGoogle Scholar
  26. 26.
    Gerblich, A.A. and Stavitsky, A.B. (1979). Regulation of the in vitro anamnestic antibody response by cyclic AMP. IV. Evidence for participation of prostaglandins of the E series in the early events. Cell. Immunol, 48, 318–328Google Scholar
  27. 27.
    Kishimoto, T. and Ishizaka, K. (1976). Regulation of the antibody response in vitro. X. Biphasic effect of cyclic AMP on the secondary anti-hapten antibody response to anti immunoglobulin and enhancing soluble factor. J. Immunol, 116, 534–541PubMedGoogle Scholar
  28. 28.
    Webb, D.R. and Osheroff, P.L. (1976). Antigen stimulation of prostaglandin synthesis and control of immune responses. Proc. Natl. Acad. Sci. USA, 73, 1300–1304PubMedCrossRefGoogle Scholar
  29. 29.
    Leung, K.H., Ehrke, M.J. and Mihich, E. (1982). Modulation of the development of cell-mediated immunity: possible role of the products of the cyclo-oxygenase and the lipoxygenase pathways of arachidonic acid metabolism. Int. J. Immunopharmacol, 4, 195–204PubMedCrossRefGoogle Scholar
  30. 30.
    Darrow, T.L. and Tomar, R.H. (1980). Prostaglandin-mediated regulation of the mixed lymphocyte culture and generation of cytotoxic cells. Cell. Immunol, 56, 172–183PubMedCrossRefGoogle Scholar
  31. 31.
    Leung, K.H. and Mihich, E. (1980). Prostaglandin modulation of development of cell-mediated immunity in culture. Nature (London), 288, 597–600CrossRefGoogle Scholar
  32. 32.
    Ting, C-C. and Hargrove, M.E. (1983). Activation of natural killer-derived cytotoxic T lymphocytes. I. Regulation by macrophage and prostaglandins. J. Immunol, 131, 1734–1741PubMedGoogle Scholar
  33. 33.
    Henney, C.S., Bourne, H.R. and Lichtenstein, L.M. (1972). The role of cyclic 3’,5’-adenosine monophosphate in the specific cytolytic activity of lymphocytes. J. Immunol, 108, 1526–1534PubMedGoogle Scholar
  34. 34.
    Strom, T.B., Carpenter, C.B., Garovoy, M.R., Austen, K.F., Merrill, J.P. and Kaliner, M. (1973). The modulating influence of cyclic nucleotides upon lymphocyte-mediated cytotoxicity. J. Exp. Med, 138, 381–391PubMedCrossRefGoogle Scholar
  35. 35.
    Hale, A.H., Evans, D.L. and Daniel, L.W. (1982). Effect of prostaglandins on elicitation of anti-viral cytolytic activity. Immunol. Lett, 4, 171–174PubMedCrossRefGoogle Scholar
  36. 36.
    Metzger, Z., Hoffeld, J.T. and Oppenheim,J.J. (1980). Macrophage-mediated suppression. I. Evidence for participation of both hydrogen peroxide and prostaglandins in suppression of murine lymphocyte proliferation. J. Immunol, 124, 983–988PubMedGoogle Scholar
  37. 37.
    Mexmain, S., Gualde, N., Aldigier, J.C., Motta, C., Chable-Rabinovitch, H. and Rigaud, M. (1984). Specific binding of 15 HETE to lymphocytes. Effects on the fluidity of plasmatic membranes. Prostagl. Leukotriene Med, 13, 93–97CrossRefGoogle Scholar
  38. 38.
    Seaman, W.E. (1983). Human natural killer cell activity is reversibly inhibited by antagonists of lipoxygenation. J. Immunol, 131, 2953–2957PubMedGoogle Scholar
  39. 39.
    Carine, K. and Hudig, D. (1984). Assessment of a role of phospholipase A2 and arachidonic acid metabolism in human lymphocyte natural cytotoxicity. Cell. Immunol, 87, 270–283PubMedCrossRefGoogle Scholar
  40. 40.
    Bray, R.A. and Brahmi, Z. (1986). Role of Iipoxygenation in human natural killer cell activation. J. Immunol, 136, 1783–1790PubMedGoogle Scholar
  41. 41.
    Droller, M.J., Perlrnann, P. and Schneider, M.U. (1978). Enhancement of natural and antibody-dependent lymphocyte cytotoxicity by drugs which inhibit prostaglandin production by tumor target cells. Cell. Immunol, 36, 154–164CrossRefGoogle Scholar
  42. 42.
    Tracey, D.E. and Adkinson, N.F. (1980). Prostaglandin synthesis inhibitors potentiate the BCG-induced augmentation of natural killer cell activity. J. Immunol, 125, 136–141PubMedGoogle Scholar
  43. 43.
    Droller, M.J., Schneider, M.U. and Perlmann, P. (1978). A possible role of prostaglandins in the inhibition of natural and antibody-dependent cell-mediated cytotoxicity against tumor cells. Cell. Immunol, 39, 165–177PubMedCrossRefGoogle Scholar
  44. 44.
    Brunda, M.J., Herberman, R.B. and Holden, H.T. (1980). Inhibition of murine natural killer cell activity by prostaglandins. J. Immunol, 124, 2682–2687PubMedGoogle Scholar
  45. 45.
    Goto, T., Herberman, R.B., Maluish, A. and Strong, D.M. (1983). Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity. J. Immunol, 130, 1350–1355PubMedGoogle Scholar
  46. 46.
    Rola-Pleszczynski, M., Gagnon, L. and Sirois, P. (1983). Leukotriene B„ augments human natural cytotoxic cell activity. Biochern. Biophys. Res. Commun, 113, 531–537CrossRefGoogle Scholar
  47. 47.
    Ramstedt, U., Ng, J., Wigzell, H., Serhan, C.N. and Samuelsson, B. (1985). Action of novel eicosanoids lipoxin A and B on human natural killer cell cytotoxicity: effects on intracellular cAMP and target cell binding. J. Immunol, 135, 3434–3438PubMedGoogle Scholar
  48. 48.
    Serhan, C.N., Fahlstadius, P.,Dahlén, S-E., Hamberg, M. and Samuelsson, B. (1985). Biosynthesis and biological activities of lipoxins. In Hayaishi, O. and Yamamoto, S. (eds.) Advances in Prostaglandin, Thromboxane and Leukotriene Research Vol. 15, pp. 163–166. (New York: Raven Press)Google Scholar
  49. 49.
    Kelly, J.P., Johnson, M.C. and Parker, C.W. (1979). Effect of inhibitors of arachidonic acid metabolism on mitogenesis in human lymphocytes: possible role of thromboxanes and products of the lipoxygenase pathway. J. Immunol, 122, 1563–1571PubMedGoogle Scholar
  50. 50.
    Bailey, J.M., Bryant, R.W., Low, C.E., Pupillo, M.B. and Vanderhoek, J.Y. (1982). Regulation of T-lymphocyte mitogenesis by the leukocyte product 15-hydroxy-eicosatetraenoic acid (15-HETE). Cell. Immunol, 67, 112–120PubMedCrossRefGoogle Scholar
  51. 51.
    Gualde, N., Chable-Rabinovitch, H., Motta, C., Durand, J., Beneytout, J.L. and Rigaud, M. (1983). Hydroperoxyeicosatetraenoic acids: potent inhibitors of lymphocyte responses. Biochim. Biophys. Acta, 750, 429–433PubMedGoogle Scholar
  52. 52.
    Low, C-E., Pupillo, M.B., Bryant, R.W. and Bailey, J.M. (1984). Inhibition of phytohemagglutinin-induced lymphocyte mitogenesis by lipoxygenase metabolites of arachidonic acid: structure-activity relationships. J. Lipid Res, 25, 1090–1095PubMedGoogle Scholar
  53. 53.
    Vanderhoek, J.Y., Bryant, R.W. and Bailey, J.M. (1980). 15-Hydroxy-5,8,11,I3-eicosatetraenoic acid: a potent and selective inhibitor of platelet lipoxygenase. J. Biol. Chem, 255, 5996–5998PubMedGoogle Scholar
  54. 54.
    Vanderhoek, J.Y., Bryant, J.W. and Bailey, J.M. (1980). Inhibition of leukotriene biosynthesis by the leukocyte product 15-hydroxy-5,8,I1,13-eicosatetraenoic acid. J, Biol. Chem, 255, 10064–10066Google Scholar
  55. 55.
    Payan, D.G. and Goetzl, E.J. (1983). Specific suppression of human T lymphocyte function by leukotriene B4. J. Immunol, 131, 551–553PubMedGoogle Scholar
  56. 56.
    Payan, D.G., Missirian-Bastian, A. and Goetzl, E.J. (1984). Human T-lymphocyte subset specificity of the regulatory effects of leukotriene B4. Proc. Natl. Acad. Sci. USA, 81, 3501–3505PubMedCrossRefGoogle Scholar
  57. 57.
    Gualde, N., Atluru, D. and Goodwin, J.S. (1985). Effect of lipoxygenase metabolites of arachidonic acid on proliferation of human T cells and T cell subsets. J. Immunol, 134, 1125–1129PubMedGoogle Scholar
  58. 58.
    Kato, K. and Murota, S. (1985). Lipoxygenase specific inhibitors inhibit murine lymphocyte reactivity to Con A by reducing IL-2 production and its action. Prostaglandl. Leukotriene Med, 18, 39–52CrossRefGoogle Scholar
  59. 59.
    Johnson, H.M. and Torres, B.A. (1984). Leukotrienes: positive signals for regulation of 7-interferon production. J. Immunol, 132, 413–416PubMedGoogle Scholar
  60. 60.
    Rola-Pleszczynski, M., Borgeat, P. and Sirois, P. (1982). Leukotriene B4 induces human suppressor lymphocytes. Biochem. Biophys. Res. Commun, 108, 1531–1537PubMedCrossRefGoogle Scholar
  61. 61.
    Rola-Pleszczynski, M. (1985). Differential effects of leukotriene B4 on T4+ and T8+ lymphocyte phenotype and immunoregulatory functions. J. Immunol, 135, 1357–1360PubMedGoogle Scholar
  62. 62.
    Mexmain, S., Cook, J., Aldigier, J-C., Gualde, N. and Rigaud, M. (1985). Thymocyte cyclic AMP and cyclic GMP response to treatment with metabolites issued from the lipoxygenase pathway. J. Irnmunol, 135, 1361–1365Google Scholar
  63. 63.
    Aldigier, J.C., Gualde, N., Mexmain, S., Chable-Ravinovitch, H., Ratinaud, M.H. and Rigaud, M. (1984). Immunosuppression induced in vivo by 15-hydroxyeicosatetraenoic acid (15HETE). Prostaglandl. Leukotriene Med, 13, 99–106CrossRefGoogle Scholar
  64. 64.
    Webb, D.R. and Nowowiejski, I. (1981). Mitogen-induced changes in lymphocyte prostaglandin levels: a signal for the induction of suppressor cell activity. Cell. Irnmunol, 41, 72–85CrossRefGoogle Scholar
  65. 65.
    Fulton, A.M. and Levy, J.G. (1981). The induction of nonspecific T suppressor lymphocytes by prostaglandin E,. Cell. Immunol, 59, 54–60PubMedCrossRefGoogle Scholar
  66. 66.
    Fischer, A., Durandy, A. and Griscelli, C. (1981). Role of prostaglandin E, in the induction of nonspecific T lymphocyte suppressor activity. J. Immunol, 126, 1452–1455PubMedGoogle Scholar
  67. 67.
    Rogers, T.J., Nowowiejski, I. and Webb, D.R. (1980). Partial characterization of a prostaglandin-induced suppressor factor. Cell. Immunol, 50, 82–93PubMedCrossRefGoogle Scholar
  68. 68.
    Webb, D.R., Wieder, K., Rogers, T.J. and Nowowiejski, I. (1980). Activation of mouse splenic suppressor cells by endogenous prostaglandin. In de Week, A., Kristensen, F. and Landy, M. (eds.) Biochemical Characterization of Lymphokines. pp. 499–501. ( New York: Academic Press )Google Scholar
  69. 69.
    Webb, D.R., Rogers, T.J. and Nowowiejski, I. (1979). Endogenous prostaglandin synthesis of and the controll or lymphocyte function. nun. NY Acad. Seí, 332, 262–270CrossRefGoogle Scholar
  70. 70.
    Rogers, T.J., Campbell, L., Calhoun, K., Nowowiejski, I. and Webb, D.R. (1982). Suppression of B-cell and T-cell responses by the prostaglandin-induced T-cell-derived suppressor (PITS). 1. Analysis of the PITS1: factor. Cell. Irmunol, 66, 269–276CrossRefGoogle Scholar
  71. 71.
    Rogers, T.J., DeHaven, J.I., Donnelly, R.P. and Lamb, B. (1984). Suppression of B-cell and T-cell responses by the prostaglandin-induced T-cell-derived suppressor (PITS). II Resolution of multiple PITS,, factors. Cell. Imrnunol, 87, 703–707CrossRefGoogle Scholar
  72. 72.
    Rogers, T.J., DeHaven, J.I. and Donnelly, R.P. (1985). Suppression of B-cell and T-cell responses by the prostaglandin-induced T-cell-derived suppressors (PITS). III. Production of PITSβ factors from T-cell hybridomas. Int. J. Irmnunopharmacol, 7, 153–156CrossRefGoogle Scholar
  73. 73.
    Webb, D.R., Wieder, KJ., Rogers, T.J., Healy, C.T. and Nowowiejski-Wieder, I. ( 1955 Chemical identification of a prostaglandin-induced T suppressor (PITS). LlnHpbDlone Re, 4, 139–149Google Scholar
  74. 74.
    Kemp, J., Louie, D., Mattingly, J., Bennett, J., Higuchi, C., Pretell, J., Horowitz, M. and Gershon, R. (1980). Suppressor cells in vitro: differential effects of indomethacin and related compounds. J. lminunopharmucal, 2, 471–489Google Scholar
  75. 75.
    Goodwin, J.S. (1980). Modulation of concanavalin-A-induced suppressor cell activation by prostaglandin E,. Cell. Immunol, 49, 421–425PubMedCrossRefGoogle Scholar
  76. 76.
    Skoldstam, L., Zoschke, D. and Messner, R. (1982). Contrasting effects of prostaglandin F, and indomethacin in modulating Con A-induced human lymphocyte proliferation and suppressor cell development. Clin. bnrnunol. Immunopathol, 25, 32–42CrossRefGoogle Scholar
  77. 77.
    Soppi, E., Eskola, J. and Ruuskanen, O. (1982). Effects of indomethacin on lymphocyte proliferation, suppressor cell function, and leukocyte migration inhibitor factor (LMIF) production. bnmunopharmacology, 4, 235–242CrossRefGoogle Scholar
  78. 78.
    Badger, A.M., Griswold, D.E. and Walz, D.T. (1982). Augmentation of concanavalin A induced immunosuppression by indomethacin. lmmunopharmacology, 4, 149–162CrossRefGoogle Scholar
  79. 79.
    Leung, K.H., Ehrke, M.J. and Mihich, E. (1983). Modification by biological products of the generation of suppressor cells in culture. Immunopharrnacology, 5, 221–237CrossRefGoogle Scholar
  80. 80.
    Donnelly, R.P. and Rogers, T.J. (1985). Inhibitors of prostaglandin synthesis block the induction of Staphylococcal enterotoxin B-activated T-suppressor cells. Cell. Imrnunol, 81, 61–70CrossRefGoogle Scholar
  81. 81.
    Rogers, C.M., Rogers, T.J. and Gilman, S.C. (1985). Effects of WY-18,251 (3-(p-chlorophenylthiazolol3,2-albenzimadazole-2-acetic acid), levamisole and indomethacin in the generation of murine T suppressor cells in vitro. J. Immunopharmacol., 7, 479–488PubMedCrossRefGoogle Scholar
  82. 82.
    Orme, I.M. and Shand, F.L. (1981). Inhibitors of prostaglandin synthetase block the generation of suppressor T cells induced by concanavalin A. bit. J. Immunopharmacol, 3, 15–19CrossRefGoogle Scholar
  83. 83.
    Orme, I.M. and Shand, F.L. (1982). Concanavalin A-induced alteration of surface marker expression on murine T cells. Int. J. Immunopharmacol, 4, 137–142PubMedCrossRefGoogle Scholar
  84. 84.
    Rogers, T.J. (1985). The role of arachidonic acid metabolites in the function of murine suppressor cells. In Goodwin, J.S. (ed.) Prostaglandins and Immunity. pp. 79–97. (Boston: Martinus Nijhoff Publishing)CrossRefGoogle Scholar
  85. 85.
    Kato, K. and Askenase, P.W. (1984). Reconstitution of an inactive antigen-specific T cell suppressor factor by incubation of the factor with prostaglandins. J. Immunol, 133, 2025–2031PubMedGoogle Scholar

Copyright information

© MTP Press Limited 1988

Authors and Affiliations

  • T. J. Rogers

There are no affiliations available

Personalised recommendations